Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce it has been granted a key patent (EP2668277B1) by the European Patent Office, protecting PromPT – its proprietary synthetic promoter development platform.
PromPT enables identification of unique gene regulatory sequence elements from natural genome-derived promoters, based on the meta-analysis of functional genomics datasets.
This technology allows for the design of synthetic promoters that are optimally tailored to drive gene expression at a desired level and specificity, facilitating the development and commercialisation of synthetic promoters for gene and cell therapy products and bioprocess applications.
Dr Michael Roberts, founder and CSO of Synpromics, commented: “Synpromics continues to innovate and this patent demonstrates our commitment to developing best-in-class synthetic promoter systems. The new patent enables multiple therapeutic and bioprocess applications and protects a key element of our technology.”
“From cell and gene therapy to biopharmaceutical manufacturing, there is a growing interest in adopting a systematic design strategy, allowing the creation of fully optimised gene expression cassettes.”